[Continuation of acid suppression therapy after H. pylori eradication].
Takahashi
Morio
M
Department of Gastroenterology and Hepatology, Koshigaya Hospital, Dokkyo University of Medicine.
Kuwayama
Hajime
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004942:Esophagitis, Peptic / Q000209:etiology / Q000517:prevention & control; D005240:Feasibility Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D009853:Omeprazole / Q000031:analogs & derivatives; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole